"Hemophilia A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Descriptor ID |
D006467
|
| MeSH Number(s) |
C15.378.100.100.500 C15.378.100.141.500 C15.378.463.500 C16.320.099.500
|
| Concept/Terms |
Hemophilia A- Hemophilia A
- Hemophilia As
- Hemophilia, Classic
- Hemophilia
- Hemophilia A, Congenital
- Congenital Hemophilia A
- Congenital Hemophilia As
- Hemophilia As, Congenital
- Classic Hemophilia
- Classic Hemophilias
- Hemophilias, Classic
- Haemophilia
Autosomal Hemophilia A- Autosomal Hemophilia A
- As, Autosomal Hemophilia
- Autosomal Hemophilia As
- Hemophilia A, Autosomal
- Hemophilia As, Autosomal
Factor VIII Deficiency- Factor VIII Deficiency
- Factor 8 Deficiency, Congenital
- Factor VIII Deficiency, Congenital
- Deficiency, Factor VIII
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia A".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia A".
This graph shows the total number of publications written about "Hemophilia A" by people in this website by year, and whether "Hemophilia A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 0 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 4 | 0 | 4 |
| 2015 | 5 | 2 | 7 |
| 2016 | 6 | 2 | 8 |
| 2017 | 6 | 0 | 6 |
| 2018 | 7 | 1 | 8 |
| 2019 | 6 | 0 | 6 |
| 2020 | 11 | 0 | 11 |
| 2021 | 14 | 0 | 14 |
| 2022 | 8 | 0 | 8 |
| 2023 | 8 | 0 | 8 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
-
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85.
-
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
-
Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024 May; 22(5):1510-1515.
-
FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
-
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
-
RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.